Journal
ONCOLOGY AND THERAPY
Volume 6, Issue 2, Pages 141-156Publisher
SPRINGER
DOI: 10.1007/s40487-018-0062-x
Keywords
Breast cancer; Combination therapy; Endocrine therapy; Hormone; Oestrogen receptor; Targeted therapy
Categories
Ask authors/readers for more resources
Oestrogen receptor (ER) is the driving transcription factor in 70% of breast cancer. Endocrine therapies targeting the ER represent one of the most successful anticancer strategies to date. In the clinic, novel targeted agents are now being exploited in combination with established endocrine therapies to maximise efficacy. However, clinicians must balance this gain against the risk to patients of increased side effects with combination therapies. This article provides a succinct outline of the principles of hormonal manipulation in breast cancer, alongside the key evidence that underpins current clinical practice. As the role of endocrine therapy in breast cancer continues to expand, the challenge is to interpret the data and select the optimal strategy for a given clinical scenario.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available